Treatment with EGCG or the EGCG derivative Y6 was found to significantly inhibit tube formation in hepatocellular carcinoma cells and angiogenesis in transplanted tumors, likely via the downregulation of the MAPK/ERK1/2 and PI3K/AKT/HIF-1α/VEGF pathways. Here, VEGFA is linked to hepatocellular carcinoma.